The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia

First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed in one-third of patients. The toxicity and efficacy of tyrosine kinase inhibitors might depend on the activity of transmembran...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncotarget
Κύριοι συγγραφείς: Galimberti, Sara, Bucelli, Cristina, Arrigoni, Elena, Baratè, Claudia, Grassi, Susanna, Ricci, Federica, Guerrini, Francesca, Ciabatti, Elena, Fava, Carmen, D’Avolio, Antonio, Fontanelli, Giulia, Cambrin, Giovanna Rege, Isidori, Alessandro, Loscocco, Federica, Caocci, Giovanni, Greco, Marianna, Bocchia, Monica, Aprile, Lara, Gozzini, Antonella, Scappini, Barbara, Cattaneo, Daniele, Scortechini, Anna Rita, La Nasa, Giorgio, Bosi, Alberto, Leoni, Pietro, Danesi, Romano, Saglio, Giuseppe, Visani, Giuseppe, Cortelezzi, Agostino, Petrini, Mario, Iurlo, Alessandra, Di Paolo, Antonello
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Impact Journals LLC 2017
Θέματα:
Research Paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675690/
https://ncbi.nlm.nih.gov/pubmed/29152138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21406
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια